Previous 10 | Next 10 |
Angion Biomedica ( NASDAQ: ANGN ) on Wednesday said it would discontinue its phase 2 JUNIPER trial evaluating its inhibitor ANG-3070 for the treatment of kidney diseases. The trial is being discontinued based upon a reassessment of the risk/benefit profile of ANG-3070 ...
UNIONDALE, N.Y., June 29, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced the discontinuation of JUNIPER...
Applied Therapeutics ( APLT ) -22% on pricing $30M equity offering . Xenon Pharmaceuticals ( XENE ) -13% on pricing $250M equity offering . Clovis Oncology ( CLVS ) -10% Zai Lab ( ZLAB ) -9% on conversion of secondary listing in Ho...
Buying Penny Stocks on June 1st? Here’s What You Need to Know With another week of trading penny stocks and blue chips getting off to a green start, investors are excited about the future. Although it is difficult to say if this bullish sentiment can continue, we do know that it ...
Angion Biomedica press release (NASDAQ:ANGN): Q1 GAAP EPS of -$0.48 misses by $0.05. Revenue of $1.65M (+345.9% Y/Y) beats by $0.73M. For further details see: Angion Biomedica GAAP EPS of -$0.48 misses by $0.05, revenue of $1.65M beats by $0.73M
-- Ended the quarter with $73M in cash and cash equivalents sufficient to fund operations well into 2023 UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization ...
-- The FDA has accepted an IND application supporting clinical development of ANG-3070 in IPF -- Phase 1b trial to be initiated to gather tolerability, safety, and pharmacokinetic data in IPF patients UNIONDALE, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp....
UNIONDALE, N.Y., April 14, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming ...
Angion Biomedica press release (NASDAQ:ANGN): FY GAAP EPS of -$1.93. Revenue of $28.31M (+883.0% Y/Y). For further details see: Angion Biomedica GAAP EPS of -$1.93, revenue of $28.31M
-- Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases -- Ended the year with nearly $89M in cash and cash equivalents UNIONDALE, N.Y., March 30, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (N...
News, Short Squeeze, Breakout and More Instantly...
Angion Biomedica Corp. Company Name:
ANGN Stock Symbol:
NASDAQ Market:
NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ: ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse...
NEW YORK, NY / ACCESSWIRE / April 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: INDUS Realty Trust, Inc. (NASDAQ:I...
NEW YORK, NY / ACCESSWIRE / March 19, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cardiovascular Systems, Inc. (NASDAQ...